Support for Your Decision to Discharge
a Patient in Acute Care.
ViroGates is now listed on NASDAQ First North in Denmark Read more here
ViroGates er nu børsnoteret på NASDAQ First North i Danmark Læs mere her
ViroGates is an international Medtech company headquartered in Denmark that was founded in 2001.
ViroGates´ product line called suPARnostic® is a commercially available test, that can measure the protein called suPAR in the blood.
More than 500 publications have followed, substantiating suPAR as one of the most promising prognostic biomarker tools for various areas of healthcare.
What does an elevated suPAR level in 12 different disease areas imply for the patients prognosis?
ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.
ViroGates publishes prospectus for its initial public offering in Copenhagen.
ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.
suPARnostic® is developed to measure the amount of suPAR protein (soluble urokinase Plasminogen Activator Receptor) in human blood.
It is the only CE-IVD certified product range applied for clinical determination of suPAR in human EDTA and heparin-plasma.
Read our latest news in our Press Room regarding our products, our company, suPAR abstracts and presentations, conferences and congresses where you can find us etc.
ViroGates publishes prospectus for its initial public offering in Copenhagen. ViroGates intends to strengthen its capital structure to intensify the continued...
ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.
We will keep you updated about the latest news on suPAR, abstracts, our products and our company…
